HOME >> BIOLOGY >> NEWS
The long road to a promising malaria vaccine started at NYU School of Medicine

NEW YORK, October 15, 2004 -- The malaria vaccine reported today to reduce life-threatening cases of the parasitic disease among children in Mozambique is based on the pioneering research of Drs. Ruth and Victor Nussenzweig and their colleagues at NYU School of Medicine.

Ruth Nussenzweig, Doc en Med, Ph.D., the C.V. Starr Professor of Medical and Molecular Parasitology, and her husband, Victor Nussenzweig, M.D., Ph.D., the Hermann M. Biggs Professor of Preventive Medicine, have devoted decades of research to preventing one of the world's biggest killers. Malaria afflicts hundreds of millions of people, causing up to 3 million deaths every year, mostly in sub-Saharan Africa. Many of its victims are young children.

In a study reported today of more than 2,000 children in Mozambique, the vaccine reduced life-threatening attacks of malaria by 58 percent, and reduced milder forms of the disease by 30 percent. The study is published in the October 16, 2004, issue of The Lancet, a medical journal.

"This is really fantastic news," says Dr. Victor Nussenzweig. "It is the first time that a vaccine has been shown to protect against severe malaria, which is a major cause of death in children in Africa. It is not yet an ideal vaccine because it is expensive, requires three doses, and it isn't known yet how durable the vaccine's protection will be, but it is a very big step forward."

The vaccine, designated RTS.S/AS02A, contains a large portion of a protein called circumsporozoite (CS) protein, which coats malaria parasites that invade the liver. This protein, which the Nussenzweigs first isolated from parasites in 1980, is the basis for some 15 malaria vaccines that now are in clinical trials or in pre-clinical testing.

The vaccine, developed by GlaxoSmithKline in collaboration with the Walter Reed Army Institute of Research, contains a large portion of the CS protein fused with a part of another
'"/>

Contact: Pamela McDonnell
Pamela.McDonnell@med.nyu.edu
212-404-3555
New York University Medical Center and School of Medicine
15-Oct-2004


Page: 1 2 3

Related biology news :

1. A new plant-bacterial symbiotic mechanism promising
2. A new plant-bacterial symbiotic mechanism promising for crop applications
3. American Association for Cancer Research provides support for promising cancer scientists
4. Sea creatures toxin could lead to promising cancer treatment
5. Epigenetic drugs, promising for breast cancer treatment
6. New study suggests promising drug combinations for sleeping sickness
7. Analysis of breast-cancer gene role offers promising target
8. Researchers report initial success in promising approach to prevent tooth decay
9. DNA highly promising predictor for successful treatment of alcoholics
10. Stem cells: Chemistry paves way toward promising therapies
11. Is liver damage down the TRAIL for a promising cancer therapy?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The long road promising malaria vaccine started NYU School Medicine

(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE San Diego ... provides the connective tissue that enhances care coordination among social ... client-level information; earned a second $1 million grant from the ... in community and; will be recognized as a "Live Well ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
Cached News: